Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neuroblastoma 3Melanoma 3Ganglioneuroblastoma 3Prostatic Neoplasms 2Multiple Myeloma 2Uveal Melanoma 1Osteosarcoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Diseases 1Carcinoma, Intraductal, Noninfiltrating 1Burkitt Lymphoma 1Breast Neoplasms 1Adult Solid Neoplasm 1

Interventions

montanide ISA 51 3Temozolomide 3Ipilimumab 3Interleukin-2 3sargramostim 2incomplete Freund's adjuvant 2glembatumumab vedotin 2aldesleukin 2Vorinostat 2Sunitinib 2Paclitaxel 2MART-1 Antigen 2Lenalidomide 2Dacarbazine 2Cyclophosphamide 2Carboplatin 2CR011-vcMMAE 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1poly ICLC 1omipalisib 1fludarabine phosphate 1fludarabine 1flt3 ligand protein 1entinostat 1cixutumumab 1cediranib 1cabozantinib 1aflibercept 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Uveal Melanoma × Colony-Stimulating Factors × Clear all
NCT01989572 2020-07-07

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Completed
815 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡